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fcholarship to guide practice and policies to enhance the
ealth of patients and populations are in great demand.
osts of health care continue to escalate, and questions
bout the effectiveness and value of strategies to prevent and
reat cardiovascular disease are growing in volume. In that
ontext, this review highlights important investigations in
utcomes research, health services research, and epidemiol-
gy published from April 2006 to March 2007. During this
eriod, many prominent contributions have expanded our
nderstanding of the patterns and burdens of cardiovascular
isease; deficiencies, challenges, and opportunities in health
are delivery and clinical decision-making; and the effect of
nterventions designed to improve care. Although this
eview cannot include every high-quality publication, it
mphasizes representative work of particular interest or
elevance to the topics of safety, effectiveness, equity, effi-
iency, and epidemiology/prevention.
afety
ne of the most important safety issues concerned the
ailure of pacemakers and implantable cardioverter-
efibrillators (ICDs). Given the recent expanding indica-
ions for ICD therapy, safety issues regarding devices have
rowing implications for costs and outcomes. Using annual
eports submitted to the U.S. Food and Drug Administra-
ion (FDA) by manufacturers from 1990 to 2002, Maisel
t al. (1) identified 17,323 device explantations for con-
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007, accepted August 27, 2007.rmed malfunctions. Overall, the rates of malfunction
eplacements were 20.7 per 1,000 implants for ICDs and
.6 per 1,000 for pacemakers, with 61 deaths attributed to
alfunction (30 pacemaker and 31 ICD). Maisel (2) also
onducted a meta-analysis of prospective device registries to
dentify trends in rates of pacemaker and ICD malfunction
etween 1998 and 2002. The registries revealed malfunc-
ions in 2,981 pacemakers and 384 ICDs. While pace-
aker reliability increased steadily over time, ICD mal-
unctions increased 4-fold, reaching a rate of 20-fold that
f pacemakers.
Amin et al. (3) used decision analysis to compare the
ptions between maintaining an unreliable device and de-
ice replacement. They found that the 2 most important
actors influencing the decision were the estimated device
ailure rate and the likely consequences of device failure.
acemaker-dependent patients fared better with device
eplacement if the estimated annual failure rate exceeded
.3%. In contrast, for primary or secondary prevention
CDs, replacement was favored for annual failure rates of at
east 3.0%. For pacemakers used for non–life-threatening
onditions, device replacement could expose the patient to
reater risks than continued device surveillance.
Statins, among the most popular cardiovascular drugs,
ave consistently defied safety concerns. In a systematic
eview of clinical trials of statins, Kashani et al. (4) quanti-
ed the risks of musculoskeletal, renal, and hepatic compli-
ations. In 35 trials including 74,102 patients, they found
ow adverse event rates; there was no significant increase in
he risks of myalgias, creatine kinase elevations, rhabdo-
yolysis, or withdrawal of therapy due to possible adverse
rug events. The risk of transaminase elevations, however,
as significantly higher (by 4.2 per 1,000 patients). Agostini
t al. (5) extended this work by examining patients who are
nder-represented in trials. In a study of 756 community-
welling veterans age 65 years and older, they found no
vidence of adverse effects from statin therapy on muscle
trength, cognition, and depressive symptoms. Setoguchi
t al. (6), linking data from a large state drug benefit
rogram with a cancer registry and a Medicare database,
ound no evidence of an impact of statin therapy—either
ositive or negative—on cancer risks.
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Ib/IIIa inhibitors (7), Alexander et al. (8) examined differ-
nces in the contribution of mis-dosing to the excess risk of
leeding between women and men. They found that women
ad a higher risk of bleeding and were more likely to receive
xcessive doses of IIb/IIIa inhibitors (46.4%) than men
17.2%). The bleeding risk associated with excess dosing
vents, however, was much greater in men. This study,
long with their prior publication, indicates an important
rea to improve the safety of care for acute coronary
yndromes (ACS).
Safety issues can also accrue with the application of
herapy to high-risk patient populations that were not
ncluded in efficacy trials. In a community-based cohort
tudy of patients hospitalized with heart failure in Ontario,
anada, between 1999 and 2001, Ko et al. (9) found that of
he patients prescribed spironolactone, 18% had elevated
erum potassium levels (5 mmol/l) and 23% received
oncurrent potassium supplementation. Many patients
reated with spironolactone had advanced renal insuffi-
iency. The study, concordant with a prior investigation of
.S. patients hospitalized with heart failure (10), identifies
widespread pattern of care posing a risk to patient safety.
The relative safety of strategies for treating patients with
T-segment elevation myocardial infarction (STEMI) who
o not respond to initial fibrinolytic therapy is not estab-
ished. In a meta-analysis, Wijeysundera et al. (11) found a
aucity of data comparing repeat fibrinolytic therapy with
onservative therapy, identifying only 3 studies including
10 patients. Repeat fibrinolytic therapy was associated with
trend toward better survival, but also with a trend toward
higher risk of reinfarction and significantly higher risk of
inor bleeding. Overall, the safety and effectiveness of this
pproach remains questionable. In the 6 trials with 908
ubjects undergoing rescue percutaneous coronary interven-
ion (PCI), there was a strong trend toward decreased
ortality and readmission and a significantly lower risk of
einfarction. Bleeding and stroke risks were almost 5-fold
reater in the rescue PCI group, revealing a mix of benefits
nd risks with the invasive rescue strategy.
Safety can also be threatened by misdiagnoses. In a
etrospective study of 1,684 patients with acute myocardial
nfarction (AMI) presenting to the emergency department,
asoudi et al. (12) revealed the implications of electrocar-
iogram (ECG) misinterpretation. In this cohort, 12% had
n undetected high-risk ECG abnormality. A missed high-
isk feature was associated with worse quality of care and a
rend toward higher mortality.
The safety of drug-eluting stents has received consider-
ble attention. In a prospective registry study, Spertus et al.
13) identified a major safety issue for patients who prema-
urely discontinue thienopyridine therapy after drug-eluting
tent placement. Among 500 patients who underwent stent
lacement for ACS, about 1 in 7 discontinued thienopyri-
ine therapy within 30 days after hospital discharge; these
atients had a nearly 10-fold higher risk of death and a 50% wncreased risk of subsequent hospitalization. This informa-
ion, in conjunction with recent concerns raised during an
DA advisory panel meeting regarding the potential risks of
cute stent thrombosis with drug-eluting stents (14), em-
hasizes the need for effective strategies to enhance adher-
nce, especially in populations in which non-adherence
oses particularly high risks.
ffectiveness
everal papers assessed whether variation in hospital per-
ormance for AMI and heart failure explains variation in
hort-term mortality rates at the institutional level (15–17).
lthough the methods varied, the message from these
tudies was consistent: variation in performance on process
easures explains relatively modest amounts of variation in
utcomes. This finding, however, should not be interpreted
o undermine the value of the therapies promoted by the
easures. Possible reasons for the weak relationship be-
ween processes of care and institutional outcomes include:
) lack of significant variation in some of the process
easures; 2) assessment of care at hospital discharge, while
elatively few deaths occur over the short term after dis-
harge; and 3) the applicability of process measures only to
ubgroups of patients (in some cases very small), while
ortality is measured for all patients. These studies support
he measurement of outcomes as complementary indicators
f quality and the expansion of process measures to new
reas and larger patient populations whenever possible.
To address the need for statistical models for measures of
utcomes suitable for public reporting, 2 studies introduced
he evidence to support claims-based, hierarchical models to
rofile hospitals on their 30-day mortality rates for heart
ailure and AMI (18,19). For both conditions, claims-based
odels were highly concordant with those derived from
edical records. These models were implemented in the
ublic reporting effort by the Centers for Medicare &
edicaid Services.
Despite the importance of reperfusion therapy for pa-
ients with STEMI, gaps in this important process of care
ersist. Alter et al. (20) determined that 23% of eligible
atients presenting with STEMI in Ontario between 1999
nd 2001 did not receive reperfusion therapy. Lack of
reatment was associated with longer time to presentation,
igher cardiovascular risk, and higher intracerebral hemor-
hage risk, leaving unresolved whether the decision to forgo
herapy results from explicit considerations of the risk-
enefit balance by clinicians and whether the best decisions
or patients are being made.
Despite the benefits of anticoagulation for atrial fibrilla-
ion (AF), many patients still do not receive therapy.
mong patients with newly diagnosed AF in a health plan,
lazer et al. (21) found that only 73% used antithrombotic
rugs of any type during the 6 months after diagnosis.
mong those with a high risk of stroke, only 59% received
arfarin, 28% received aspirin, and 24% neither therapy.
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Year in Epidemiology, Health Services Research, and Outcomes Research December 4, 2007:2254–62hose with transient AF were significantly less likely to be
reated, and estimated stroke risk had little association with
herapy. These patterns of care conflict with current guide-
ines (22), which support identical strategies of antithrom-
otic therapy for both paroxysmal and persistent AF as well
s therapy that is calibrated to the patient’s risk for stroke.
Elkayam et al. (23), using data from ESCAPE (Evalua-
ion Study of Congestive Heart Failure and Pulmonary
rtery Catheterization Effectiveness), studied the associa-
ion between the use of vasodilators and inotropes and the
-month risk of all-cause mortality and rehospitalization
mong patients with acute decompensated heart failure.
reatment site was a stronger correlate of inotropes or
asodilator use than any patient factor, suggesting that
reatment choice was influenced more by institutional
ulture than the patients’ clinical condition. Overall,
notropes with or without concomitant vasodilators were
ssociated with a higher risk of death, possibly account-
ng for some of the national hospital-level variation in
eart failure mortality.
In GRACE (Global Registry of Acute Coronary Events),
teg et al. (24) showed that patients with an AMI partici-
ating in randomized controlled trials had a lower baseline
isk and experienced lower mortality than non-enrolled
atients, even among those nonenrolled patients who were
ligible for the treatments. The mortality difference was not
ntirely explained by differences in baseline risk, use, and
ype of reperfusion therapy, and/or delays in presentation.
his study increases concerns about the degree to which
xisting clinical trials can be extrapolated to larger popula-
ions. Systems can have a powerful effect on improving the
ffectiveness of treatments. Roumie et al. (25) performed a
rial demonstrating that an intervention to improve blood
ressure control that included a patient education compo-
ent resulted in better blood pressure control than those
ncluding only provider education. More studies are needed
o understand how nonpharmacologic adjunctive interven-
ions can improve effectiveness and which components of
ultifaceted interventions achieve the best results.
Several studies advanced our knowledge about door-to-
alloon times for patients undergoing primary PCI for
TEMI. In the NRMI (National Registry of Myocardial
nfarction) -3 and -4 cohorts, McNamara et al. (26) found
strong relationship between door-to-balloon times and
isk of mortality; patients whose PCI was delayed had a
early 50% greater odds of dying than those treated within
he recommended 90 min. Pinto et al. (27), using data from
92,509 patients at 645 NRMI hospitals, reported that the
ortality advantage of primary PCI over fibrinolysis
ecreased with increasing delays in PCI, and that the
break-even” point, where there was no advantage to
rimary PCI, differed substantially based on patient age
nd infarct location.
An understanding of the importance of reducing the time
f primary PCI for STEMI, however, does not provide
nsights into how to improve this time. Bradley et al. t28–30) published a series of articles that identified factors
ssociated with faster primary PCI times. These process
trategies included having emergency medicine physicians
ctivate the catheterization laboratory, having a single call to
central page operator activate the laboratory, having the
mergency department activate the catheterization labora-
ory while the patient is en route to the hospital, expecting
taff to arrive in the catheterization laboratory within 20 min
f being paged, having an attending cardiologist always on
ite, and providing real-time data feedback. A national
ampaign, sponsored by the American College of Cardiol-
gy, is underway to promote faster times in part based on
he implementation of a number of these strategies (31).
Lack of adherence can also diminish effectiveness of
roven therapies. Kramer et al. (32) examined health plan
ecords from 17,035 members of 11 health plans who had
n AMI in 2001, survived at least 1 year, and maintained
nsurance coverage. At 1 year, only 45% were adherent to
eta-blockers, with the biggest decline between 30 and 90
ays. Ho et al. (33) reported that by 1 year after AMI, more
han 10% of patients had discontinued aspirin, beta-
lockers, and statins, and almost another 15% discontinued
t least 1 of the medications. Overall, discontinuations were
ssociated with an increased risk of mortality. The need for
n understanding of effective strategies to improve adher-
nce was addressed in a randomized trial by Lee et al. (34)
hat found a positive impact of an intensive pharmacy care
rogram on medication adherence, medication persistence,
nd blood pressure levels. The evidence of the effectiveness
f the intervention was bolstered by the finding that after
iscontinuation of the program, adherence declined. This
nding, however, also suggests that even after an intensive
ntervention, sustainability cannot be assumed. Whether
uch intensive interventions are realistic on a large scale
emains unknown.
quity
any studies documented a gap in black–white life expect-
ncy; Harper et al. (35) reported that between 1993 and
003, the life expectancy gap declined by 1 year, but remains
ubstantial (4.5 years less in blacks). For women, heart
isease was the most important contributor, accounting for
bout 30% of the gap in 1983, 1993, and 2003. For men,
eart disease became most important in 2003, accounting
or 21% of the gap. The authors thus identify the impor-
ance of targeting cardiovascular disease as a means of
educing racial inequalities in mortality.
Environmental stressors have been suggested as exacer-
ating factors in hypertension, particularly among racial
inorities. Brown et al. (36), with data from SWAN (Study
f Women’s Health Across the Nation), investigated the
mpact of perceived unfair treatment, including perceived
acism, sexism, and ageism on blood pressure. While per-
eived unfair treatment was reported by substantial propor-
ions of racial and ethnic minorities, including 65% of
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December 4, 2007:2254–62 Year in Epidemiology, Health Services Research, and Outcomes Researchfrican Americans, 60% of Chinese, 36% of Japanese, and
7% of Hispanics, this factor was not correlated with
levated blood pressure levels.
The relationship between socioeconomic status and out-
omes in patients with cardiovascular disease was the focus
f several studies. Rathore et al. (37), in a national study of
edicare patients hospitalized with heart failure, reported
hat lower socioeconomic status was associated with a 10%
igher risk of mortality and an 8% higher risk of readmis-
ion in the year after discharge, independent of patient
aseline characteristics. A Canadian study of 5,622 patients
resenting to emergency departments with an AMI simi-
arly found that the importance of socioeconomic status as a
redictor of mortality was not substantially attenuated by
djustment for baseline patient factors and hospital factors
38). However, the effect of socioeconomic status was
argely confined to patients who were not revascularized. In
ontrast, in a study of 2,142 patients with AMI at 19 U.S.
enters, Bernheim et al. (39) showed that low socioeco-
omic status was associated with worse clinical status on
dmission and poorer quality of care. These differences,
articularly clinical factors, explained much of their higher
isk of mortality. A clearer understanding of the mediators
f adverse outcomes would provide perspective on the
ptimal policy strategies for improving outcomes in patients
f low socioeconomic status; economic policies to alleviate
overty would likely have an important effect.
Avendano et al. (40), in a longitudinal study of 10
estern populations during the 1990s, determined that
ower socioeconomic status was associated with a higher risk
f mortality from ischemic heart disease. The disparities
ere largest in the Scandinavian countries and England/
ales and less pronounced in the southern European
ountries, reflecting the distribution of cardiovascular risk
actors in Europe. In a study of 4 National Health and
utrition Examination Surveys, Kanjilal et al. (41) found
hat socioeconomic gaps in risk factors in the U.S. have not
hanged substantially or have even worsened from 1971 to
002. While the prevalence of risk factors declined in all
ducation and income groups, reductions in cholesterol and
moking were more pronounced in the higher education and
ncome groups. Meanwhile, increases in diabetes dispropor-
ionately affected those with low incomes and education.
Albert et al. (42) studied the relationship between socio-
conomic status and both traditional and novel risk factors
or cardiovascular events over 10 years of follow-up in the
omen’s Health Study. At baseline, median total choles-
erol, low-density lipoprotein, triglyceride, C-reactive pro-
ein, intercellular adhesion molecule-1, fibrinogen, and
omocysteine levels decreased progressively, and high-
ensity lipoprotein levels increased with increasing educa-
ion and income levels. The risk of incident cardiovascular
vents decreased with increasing education and income. For
ncome, cardiovascular event rates were largely explained by
ifferences in risk factors; however, this was not true for
ducation, perhaps suggesting that different pathways me- biate the relationships between income, education, and
ardiovascular events. The strength of the associations in
his study was notable given that the subjects were all health
are professionals. In sum, several studies published during
he year suggest that effective preventive efforts would
ubstantially reduce the burden of cardiovascular disease
hat disproportionately affects patients with lower socioeco-
omic status.
Hospitals in the Veterans Affairs (VA) system provide an
pportunity to examine disparities in a system designed to
rovide equal access. Groeneveld et al. (43) found that VA
ospitals with larger proportions of black patients had larger
acial differences in cardiovascular procedure use. In con-
rast, Kressin et al. (44) found similar subsequent procedure
ates and functional status after positive nuclear myocardial
erfusion tests regardless of patient race in a study of 5 VA
ospitals. These studies seem to suggest that while race
nfluences procedure use in the VA, once patients receive
iagnostic testing that indicates high risk, they are treated
imilarly and have similar outcomes. There is still much to
nderstand about the consequences of differences in diag-
osis and treatment by gender and race.
fficiency
nbridled growth in the cost of health care in the U.S. has
ncreased the scrutiny of the utilization of cardiovascular
are, particularly of diagnostic and therapeutic procedures.
n an assessment of the use of cardiovascular services in
ee-for-service Medicare beneficiaries between 1999 and 2004,
ayes et al. (45) found an average annual change in volume of
.7% per beneficiary for all cardiovascular services. The annual
rowth in utilization was greatest for nuclear medicine (16.1%)
nd echocardiography (10.5%). The decline in bypass surgeries
4.0%) was offset by an increase in angioplasty (7%). The
ustainability of this growth in cardiovascular services in the
uture is questionable.
The striking rise in the utilization of cardiovascular
maging has generated greater pressures for professional
ccountability. During the year, the American College of
ardiology published appropriateness criteria for imaging in
he areas of cardiovascular computed tomography/magnetic
esonance imaging, transthoracic echocardiography, and
ransesophageal echocardiography (46,47). These docu-
ents, reflecting expert consensus, identify clinical scenarios
here the use of a specific imaging modality is considered
ppropriate, inappropriate, or of uncertain appropriateness.
ow these criteria can be integrated into clinical care, and
hether their use will result in a meaningful decrement in
he inappropriate utilization of cardiovascular imaging are
ssues for further study.
Policies and programs to constrain costs have proliferated
n response to the alarming growth in the costs of medical
are. Hsu et al. (48) determined the effect of caps on annual
rug benefits for Medicare beneficiaries. Compared with
eneficiaries without drug benefit caps, those with caps had
s
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Year in Epidemiology, Health Services Research, and Outcomes Research December 4, 2007:2254–62ubstantially lower pharmacy costs (by 31%); total medical
osts, however, were only 1% lower. Those with caps were
% more likely to visit the emergency department, 13%
ore likely to experience a non-elective hospitalization, and
2% more likely to die. This may have been mediated, in
art, by lower adherence to drug therapy for hypertension,
yslipidemia, and diabetes among the patients with limited
enefits. Indeed, blood pressure, cholesterol levels, and
lycated hemoglobin levels were higher in the group with
aps.
Rahimi et al. (49) determined the relationship between
nancial barriers to care and medications in a cohort of
,498 survivors of a hospitalization for AMI. The preva-
ence of self-reported financial barriers to health care ser-
ices or medications was 18.1% and 12.9%, respectively, and
arriers were relatively common even among insured pa-
ients with annual incomes exceeding $70,000. Financial
arriers were associated with more angina, poorer quality of
ife, and higher risk of rehospitalization in the year after
ospitalization. The policy implication is that possessing
ealth insurance alone does not necessarily address the
eleterious effects of financial barriers to care.
Soumerai et al. (50) assessed rates of non-adherence
elated to drug costs in a national sample of 13,835
on-institutionalized Medicare beneficiaries. Overall, about
in every 9 men and 1 in every 7 women reported
ost-related medication non-adherence. Among disabled
nrollees with 4 or more comorbidities, rates were markedly
igher, exceeding 50% among those without drug coverage
nd 25% among those with coverage.
Several cost-effectiveness analyses have assessed the eco-
omic attractiveness of electrophysiologic interventions.
han et al. (51) found that catheter ablation of AF was not
avored for patients with a relatively low risk of stroke
1.4% annually). It may be economically attractive for
atients with moderate risk (at least 3.0% annually); how-
ver, this assumes an 80% overall success rate at achieving
inus rhythm and a reduction in the risk of stroke of 42% by
atheter ablation. Because such success rates and benefits
ave not been firmly established, it remains unclear whether
atheter ablation for AF will be a cost-effective strategy in
ny population.
Several studies focused on the economic implications of
CDs. Using data from the industry-sponsored MADIT
Multicenter Automatic Defibrillator Implantation Trial)-II
ver 3.5 years, Zwanziger et al. (52) found that the average
ain in the defibrillator arm of the trial was 0.167 years (2
onths) at an estimated additional cost of $39,200. This
ranslated into an incremental cost-effectiveness ratio of
235,000 per year of life saved, which is markedly more
ostly than what is traditionally considered economically
ttractive. Although a 12-year time horizon resulted in
etter cost-effectiveness ratios, even under best-case as-
umptions, the incremental cost-effectiveness ratio per year
f life saved was still relatively high ($78,000). Mark et al.
53), in the economic analyses from the industry-sponsored bCD-HeFT (Sudden Cardiac Death in Heart Failure
rial), reported that relative to medical therapy, ICD
herapy was associated with a lifetime cost-effectiveness
atio of $41,530 per quality-adjusted life-year. This calcu-
ation assumed, however, that the benefits of ICD therapy
een in SCD-HeFT extended to 8 years after implantation.
Microvolt T-wave alternans (MTWA) testing has been
roposed as a strategy to identify patients with left ventric-
lar systolic dysfunction who will benefit from ICD therapy.
lthough MTWA testing is covered by the Centers for
edicare & Medicaid Services, its cost-effectiveness is not
lear. In an economic analysis in a population similar to that
f MADIT-II, Chan et al. (54) found that MTWA
creening followed by ICD therapy in the MTWA non-
egative population rendered ICD therapy cost-effective, in
ontrast to an ICD-for-all-patients approach, which was
ot cost-effective (similar to the findings of Zwanziger
52]). However, because a screening strategy will miss a
mall number of patients who would benefit from ICD
herapy, the challenge for society is to determine the value of
aving a life.
Yao et al. (55) assessed the economics of cardiac resyn-
hronization therapy for patients with heart failure and
ardiac dyssynchrony. Compared with medical therapy and
ith a lifetime perspective for a patient age 65 years, cardiac
esynchronization therapy had an estimated cost-
ffectiveness ratio of €7,538 per quality-adjusted life-year
ained. Adding an ICD to the cardiac resynchronization
evice had a substantially less attractive incremental cost-
ffectiveness ratio of €47,909 per quality-adjusted life-year
ained. Although these findings suggest the economic
ttractiveness of resynchronization therapy, the overall cost
ill be high, as many people are eligible.
The cost-effectiveness of guidelines has rarely been eval-
ated. Manuel et al. (56) compared the effectiveness and
fficiency of different national guidelines for the use of
tatins for preventing deaths from coronary artery disease.
lthough the guideline developers were exposed to the same
cience, each national guideline provided somewhat differ-
nt recommendations. The Australian and British guide-
ines were estimated to save the most lives, but the New
ealand guideline prevented almost as many deaths while
reating about a third less patients (12.9% vs. 17.3%). The
.S. guideline recommended treating about twice as many
eople as the New Zealand guideline with no substantial
ncrease in the number of deaths averted.
Several articles raised concerns about conflicts of interest,
hich also introduce inefficiencies into the health care
ystem. Jørgensen et al. (57), in a comprehensive Cochrane
eview, determined that industry-supported reviews of drugs
ere less transparent, had fewer reservations about meth-
dological limitations of the included trials, and had more
avorable conclusions than Cochrane reviews of the same
opics. Ridker and Torres (58), in a review of 324 superiority
rials of cardiovascular medicines, found that studies funded
y for-profit organizations more often reported positive
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oss et al. (59) evaluated laws in Vermont and Minnesota
ntended to promote transparency in payments from indus-
ry to physicians, finding substantial gaps in reporting and
vidence of payments in excess of American Medical Asso-
iation guidelines.
pidemiology and Prevention
pidemiological studies continue to expand our under-
tanding of the importance of both novel and established
ardiovascular risk factors and the distribution and out-
omes of cardiovascular disease in the population. Ogden
t al. (60) from the Centers for Disease Control and
revention estimated the prevalence and trends in over-
eight and obesity from 1999 to 2004. They reported that
n 2003 to 2004, 17.1% of U.S. children and adolescents
ere overweight and 32.2% of adults were obese. In children
nd adolescents, obesity prevalence rose from 14.0% to
8.2% in male children and adolescents and from 13.8% to
6.0% in female children and adolescents. Among adult
en, the rate of obesity increased from 27.5% to 31.1%,
hile in women, although the prevalence was stable, obesity
ffected 1 in 3.
The consequences of the obesity epidemic for rates of
iabetes are profound. In the Framingham Heart study, Fox
t al. (61) found a doubling of the incidence of type 2
iabetes over the past 30 years. They also found that most of
he absolute increase occurred in people with a body mass
ndex (BMI) of 30 kg/m2 or more. The impact of obesity on
ardiovascular outcomes is also substantial. Adams et al.
62) assessed the association between obesity and risk of
eath in a study of 527,265 men and women in a National
nstitutes of Health-American Association of Retired Per-
ons cohort, finding a strong association with risk of death
n both men and women, in all racial and ethnic groups, and
t all ages. After taking into account other health conditions
nd smoking, they found an increased risk even with
oderately higher BMI. Compared with people who, at age
0, had a BMI between 23.5 and 24.9 kg/m2, those who
ere overweight had a 50% higher risk and those who were
bese had between 2- and 3-fold greater risk.
Although the benefits of structured exercise are docu-
ented, the effects of energy expenditures during free-living
ctivity on outcomes have not been characterized. In a study
f high-functioning, community-dwelling older adults,
anini et al. (63) identified a strong association between
ree-living activity energy expenditure and mortality. Every
tandard deviation increase in energy expenditure—the
quivalent of about 75 min of activity such as everyday
hores or non-sitting work daily—was associated with a
2% lower risk of death.
Several important diet articles were published this year. A
omprehensive meta-analysis of 89 randomized and obser-
ational studies found little evidence to support the routine
se of omega-3 fats to reduce risks of death or cardiovas- tular events (64). Results were similar with long chain
ersus short chain and dietary advice versus supplements.
he results of individual studies varied widely; an analysis of
bservational studies alone suggested benefits, raising ques-
ions about the influences of confounders in this subgroup
f studies. In a study of the benefits of antioxidant supple-
ents for primary and secondary prevention by the
ochrane Collaboration (65), evidence emerged that beta
arotene, vitamin A, and vitamin E may increase mortality.
he effects of vitamin C and selenium were less certain.
The PREDIMED (Prevencio´n con Dieta Mediterra´nea)
tudy (66) provided some support for the Mediterranean
iet. Investigators assigned 772 subjects to 1 of 2 Mediter-
anean diets or a low-fat diet. The subjects in the Mediter-
anean diet groups received nutritional education and either
ree virgin olive oil, or 1 liter per week of free nuts. At 3
onths, subjects in the 2 Mediterranean diet groups had
ore favorable plasma glucose levels, systolic blood pres-
ures, and cholesterol to high-density lipoprotein choles-
erol ratios. Further, the Mediterranean diet with olive oil
educed C-reactive protein levels by 0.54 mg/l (95% confi-
ence interval 1.04 to 0.03 mg/l) compared with the low-fat
iet. The impact of these changes in risk factor profiles
esulting from Mediterranean diets on cardiovascular out-
omes, however, remains unclear. In a parallel-design trial
f garlic in 192 adults, there were no benefits on low-density
ipoprotein levels (67). In another trial, McMillan-Price
t al. (68) randomized 129 overweight and obese young
dults to 1 of 4 reduced fat, high-fiber diets with varying
lycemic indexes. Weight loss over 12 weeks did not differ
s a function of glycemic index, but the superior diet for
ardiovascular risk reduction was high carbohydrate and low
lycemic index. In a comparison of 4 popular diet programs,
ardner et al. (69) found the greatest weight loss with the
tkins diet compared with similar weight losses with the
rnish, LEARN, and Zone diets. Metabolic effects were
lso most favorable with the Atkins diet. Based on obser-
ational data from the Nurses Health Study, Halton et al.
70) found no evidence of an excess risk associated with a
ow carbohydrate diet over 20 years of follow-up, while a
igh glycemic load was associated with a higher risk of heart
isease. A low carbohydrate diet with vegetable sources of
at and protein appeared associated with lower risk.
Several important studies of trends were published, in-
luding 2 on AF from Olmsted County. One study revealed
n increase in the age-adjusted incidence of AF, with a
elative increase of 21% over 21 years (71). Based upon this
rajectory, the authors estimate that there may be 15.9
illion Americans with AF by 2050. In another article in
he same timeframe (72), the early (4 month) mortality risk
f AF was almost 10-fold higher for those with newly
iagnosed AF. Although AF was associated with a persis-
ently higher mortality in longer-term follow-up, the mag-
itude of this risk was substantially lower. Over 21 years of
he study, that risk remained unchanged. In another impor-
ant trend study from Olmsted County, Gerber et al. (73)
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he community, with a shift toward deaths that occurred out
f the hospital and due to non-coronary causes. In a study of
edicare beneficiaries hospitalized with AMI in 4 U.S.
tates between 1992 and 2001, Masoudi et al. (74) found
ubstantial increases in the burden of comorbidity in this
lderly population. Although the quality of care with aspi-
in, beta-blockers, and angiotensin-converting enzyme in-
ibitors improved significantly during the time of the study,
iminishing proportions of patients met eligibility criteria
or these evidence-based therapies. Unadjusted mortality
ncreased over time, but adjusted mortality improved during
he time of the study. These trends likely reflected both the
arked increase in disease severity and simultaneous im-
rovements in care over time.
Several studies focused upon the relationship between
epressive symptoms and cardiovascular disease. Sherwood
t al. (75), based on a study of 204 patients with heart
ailure, found that patients with depressive symptoms had a
orse prognosis, with a 56% increased risk of death or
ardiovascular hospitalization. Paradoxically, antidepressant
se was associated with a 75% higher risk of death or
ardiovascular hospitalization after adjusting for the severity
f the depressive symptoms. The benefits of antidepressant
herapy in patients with heart failure thus remain debatable.
uo et al. (76) reported in a prospective, longitudinal study
f 2,675 women with coronary disease that depressive
ymptoms had an effect on self-rated health over 3 years that
ivaled the impact of major cardiac events. In a registry
tudy, Mallik et al. (77) found that the prevalence of
epressive symptoms is particularly high in younger women
fter an AMI, with a prevalence of 40% in women age 60
ears and younger. In another study from this registry, the
ame investigators showed that depressive symptoms after
n AMI, whether they persist, subside, or develop in the
rst month after hospitalization, are associated with worse
utcomes after the AMI (78). Further studies of effective
nterventions to reduce the adverse impact of depression on
ardiovascular disease outcomes are clearly needed.
onclusions
he past year has witnessed substantial advances in our
nderstanding of the patterns of cardiovascular diseases
nd the care and outcomes of these conditions in the
opulation. The increasing volume of high-quality stud-
es reflects growing appreciation of the need to develop
pproaches to identify populations at risk for cardiovas-
ular disease; intervene with effective strategies to prevent
ardiovascular events; improve the care of those who have
vents despite our best efforts; and to do so efficiently,
afely, and equitably. While much more must be done,
he year provided clinicians with a wealth of information
nd tools to achieve the central goal of providing better
are to patients.eprint requests and correspondence: Dr. Harlan M. Krumholz,
ale University School of Medicine, Internal Medicine, P.O. Box
08088, 333 Cedar Street, New Haven, Connecticut 06520-8088.
-mail: harlan.krumholz@yale.edu.
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